L-chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro

被引:49
作者
Reinke, RA
Lee, DJ
Mcdougall, BR
King, PJ
Victoria, J
Mao, YQ
Lei, XY
Reinecke, MG
Robinson, WE
机构
[1] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA
[2] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA
[3] Texas Christian Univ, Dept Chem, Ft Worth, TX 76129 USA
关键词
real-time polymerase chain reaction; acquired immune deficiency syndrome; experimental therapeutics; biochemistry; steady-state kinetic analyses; provirus;
D O I
10.1016/J.VIROL.2004.06.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human immunodeficiency virus (HIV) integrase (IN) must covalently join the viral cDNA into a host chromosome for productive HIV infection. L-Chicoric acid (L-CA) enters cells poorly but is a potent inhibitor of IN in vitro. Using quantitative real-time polymerase chain reaction (PCR), L-CA inhibits integration at concentrations from 500 nM to 10 muM but also inhibits entry at concentrations above I muM. Using recombinant HIV IN, steady-state kinetic analyses with L-CA were consistent with a noncompetitive or irreversible mechanism of inhibition. IN, in the presence or absence Of L-CA, was successively washed. Inhibition of IN diminished, demonstrating that L-CA was reversibly bound to the protein. These data demonstrate that L-CA is a noncompetitive but reversible inhibitor of IN in vitro and of HIV integration in vivo. Thus, L-CA likely interacts with amino acids other than those which bind substrate. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:203 / 219
页数:17
相关论文
共 91 条
[1]  
ABRAMS D, 1996, AIDS HIV TREATMENT D, V8, P50
[2]   Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. [J].
Albrecht, MA ;
Bosch, RJ ;
Hammer, SM ;
Liou, SH ;
Kessler, H ;
Para, MF ;
Eron, J ;
Valdez, H ;
Dehlinger, M ;
Katzenstein, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :398-407
[3]   STEADY-STATE KINETIC-STUDIES WITH THE POLYSULFONATE U-9843, AN HIV REVERSE-TRANSCRIPTASE INHIBITOR [J].
ALTHAUS, IW ;
CHOU, JJ ;
GONZALES, AJ ;
LEMAY, RJ ;
DEIBEL, MR ;
CHOU, KC ;
KEZDY, FJ ;
ROMERO, DL ;
THOMAS, RC ;
ARISTOFF, PA ;
TARPLEY, WG ;
REUSSER, F .
EXPERIENTIA, 1994, 50 (01) :23-28
[4]   KINETIC-STUDIES WITH THE NONNUCLEOSIDE HIV-1 REVERSE-TRANSCRIPTASE INHIBITOR-U-88204E [J].
ALTHAUS, IW ;
CHOU, JJ ;
GONZALES, AJ ;
DEIBEL, MR ;
CHOU, KC ;
KEZDY, FJ ;
ROMERO, DL ;
PALMER, JR ;
THOMAS, RC ;
ARISTOFF, PA ;
TARPLEY, WG ;
REUSSER, F .
BIOCHEMISTRY, 1993, 32 (26) :6548-6554
[5]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[6]   Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patients [J].
Baldanti, F ;
Paolucci, S ;
Maserati, R ;
Maggiolo, F ;
Pan, A ;
Castelli, F ;
Gulminetti, R ;
Comolli, G ;
Chiesa, A ;
Gerna, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (05) :380-384
[7]   Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1 [J].
Beale, KK ;
Robinson, EW .
ANTIVIRAL RESEARCH, 2000, 46 (03) :223-232
[8]   RETROVIRAL INTEGRATION - STRUCTURE OF THE INITIAL COVALENT PRODUCT AND ITS PRECURSOR, AND A ROLE FOR THE VIRAL IN PROTEIN [J].
BROWN, PO ;
BOWERMAN, B ;
VARMUS, HE ;
BISHOP, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2525-2529
[9]   Dynamic, thermodynamic, and kinetic basis for recognition and transformation of DNA by human immunodeficiency virus type 1 integrase [J].
Bugreev, DV ;
Baranova, S ;
Zakharova, OD ;
Parissi, V ;
Desjobert, C ;
Sottofattori, E ;
Balbi, A ;
Litvak, S ;
Tarrago-Litvak, L ;
Nevinsky, GA .
BIOCHEMISTRY, 2003, 42 (30) :9235-9247
[10]  
BUHLER MF, 1963, AN ASOC QUIM ARGENT, V51, P330